Atara Biotherapeutics (ATRA) EPS (Basic) Growth (3y) (2016 - 2026)
Atara Biotherapeutics (ATRA) EPS (Basic) Growth (3y) (2016 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.41 Bn | 130.56 Bn | 2.84 Bn | 6.85% |
| 2 | Regeneron Pharmaceuticals | 86.12 Bn | 78.12 Bn | 3.93 Bn | 11.71% |
| 3 | Argenx Se | 64.41 Bn | 59.23 Bn | 1.37 Bn | 64.84% |
| 4 | Moderna | 57.56 Bn | 52.43 Bn | 52.00 Mn | 18.44% |
| 5 | BeOne Medicines | 42.06 Bn | 36.96 Bn | 1.53 Bn | 37.21% |
| 6 | Alnylam Pharmaceuticals | 30.95 Bn | 27.65 Bn | 992.69 Mn | 36.73% |
| 7 | BioNTech SE | 27.48 Bn | 9.09 Bn | 668.28 Mn | -26.87% |
| 8 | Insmed | 27.31 Bn | 26.15 Bn | 358.27 Mn | 67.51% |
| 9 | Royalty Pharma | 27.04 Bn | 26.20 Bn | - | -38.31% |
| 10 | Atara Biotherapeutics | 139.36 Mn | 122.80 Mn | 439,000.00 | 73.31% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 72.72% |
| Mar 31, 2026 | 74.61% |
| Dec 31, 2025 | 75.46% |
| Sep 30, 2025 | 75.09% |
| Jun 30, 2025 | -64.95% |
| Mar 31, 2025 | 29.30% |
| Dec 31, 2024 | 59.21% |
| Sep 30, 2024 | 49.37% |
| Jun 30, 2024 | 48.52% |
| Mar 31, 2024 | 35.87% |
| Dec 31, 2023 | 19.62% |
| Sep 30, 2023 | 10.53% |
| Jun 30, 2023 | 15.95% |
| Mar 31, 2023 | 16.17% |
| Dec 31, 2022 | 21.82% |
| Sep 30, 2022 | 14.40% |
| Jun 30, 2022 | 28.33% |
| Mar 31, 2022 | 34.17% |
| Dec 31, 2021 | -31.81% |
| Sep 30, 2021 | 11.05% |